Compare Pfizer Inc (PFE) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard S&P 500 ETF — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Vanguard S&P 500 ETF trades at $714.52 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 11.3× Pfizer Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard S&P 500 ETF for 55 Days on average.
| PFE | VOO | |
|---|---|---|
Market Cap | $159.59B | $1.80T |
Volume | 30,937,010 | 4,660,398 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $716.17 |
52-Week Low | $23.67 | $580.93 |
Typical Hold Time | 158 Days | 55 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
VOO trades at $714.42, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF's dividend yield is modest, and recent news highlights its role in long-term wealth building amid expectations of slowing S&P 500 profit growth. Short interest increased 46.9% in September, indicating some bearish sentiment.
The outlook for VOO remains positive for buy-and-hold investors, supported by its low-cost exposure to the S&P 500. Risks include macroeconomic headwinds from potential Fed rate hikes and elevated short interest. Analyst consensus favors long-term holding, with the ETF seen as a core portfolio component for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
